Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancer
Question
Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancer
Direct answer
High objective response rates in first-line HNSCC expand Rybrevant potential addressable market beyond EGFR non-small cell lung cancer into multi-indication solid tumor combinations. — bullish pressure on JNJ via pharmaceutical pipeline TAM expansion via multi-indication label development.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-26
- Published
- 2026-10-26
- Revision
- 1 · 2026-10-27
Cite as: Market Ontology, “Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancer”, revision 1, evidence through 2026-10-26. https://marketontology.com/catalysts/2026-10-26/johnson-johnson-amivantamab-combo-reports-77-response-rate-in-head-and-neck-canc-ec9a10
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| JNJ | ▲Bull | 1–3 months | pharmaceutical pipeline TAM expansion via multi-indication label development | 79 |
Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancer
High objective response rates in first-line HNSCC expand Rybrevant potential addressable market beyond EGFR non-small cell lung cancer into multi-indication solid tumor combinations. — bullish pressure on JNJ via pharmaceutical pipeline TAM expansion via multi-indication label development.
Subcutaneous amivantamab achieved a 77% overall response rate in first-line advanced head and neck squamous cell carcinoma.
- SourceSubcutaneous amivantamab achieved a 77% overall response rate in first-line advanced head and neck squamous cell carcinoma.
- TransmissionHigh objective response rates in first-line HNSCC expand Rybrevant potential addressable market beyond EGFR non-small cell lung cancer into multi-indication solid tumor combinations.
- SummaryJohnson & Johnson posted a 77% overall response rate in the OrigAMI-4 Phase 1b/2 study. The trial assessed subcutaneous amivantamab with pembrolizumab and chemotherapy in head and neck cancer. The data supports expanding amivantamab clinical programs into first-line solid tumors.
- JNJDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- JNJ closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- JNJ price vs. pre-event level
- JNJ volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| JNJ | Bullish | 266.30 2026-10-26 | Pending | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-27Bristol Myers reports positive Phase 3 data on iza-brenBMY JNJ
- 2026-10-26Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck StudyJNJ
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ
- 2026-10-26Johnson & Johnson Reports 77% Response Rate in OrigAMI-4 Head and Neck Cancer TrialJNJ
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ
- 2026-10-26Johnson & Johnson Subcutaneous Amivantamab Hits 77% Response Rate in Head and Neck StudyJNJ
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ MRK+0.86%
- 2026-10-26J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous AmivantamabJNJ MRK+0.86%
Find trades for this development
Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.
First 10 runs free
See today's live cards
Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.